Company news

Evolus, Inc. Common Stock news in 2023

Evolus, Inc. Common Stock's news releases, calls and decks from 2023, newest first.

View company

Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe

December 19, 2023

Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau®

November 6, 2023

Evolus to Report Third Quarter 2023 Results

October 24, 2023

Evolus Announces Inducement Grants for New Chief Marketing Officer

August 22, 2023

Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer

August 20, 2023

Evolus Unveils New Branding for Flagship Product Jeuveau® to Reflect Growing and Evolving Consumers

August 7, 2023

Evolus Reports Second Quarter 2023 Results and Provides Business Update

August 1, 2023

Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue

July 26, 2023

Evolus to Report Second Quarter 2023 Results and Provide Business Update

July 18, 2023

Evolus Launches Nuceiva® (botulinum toxin type A) in Italy

June 28, 2023

Evolus Announces Successful Completion of Phase 2 Study Evaluating “Extra-Strength” Dose of Jeuveau ®

June 21, 2023

Evolus Reaches 1 Million Redemptions in its Evolus Rewards™ Patient Loyalty Program

June 7, 2023

Evolus Reports First Quarter 2023 Results and Provides Business Update

May 8, 2023

Evolus Announces Expansion into U.S. Dermal Filler Market with Evolysse™, a First-Generation Cold Technology HA by Symatese

May 8, 2023

Evolus to Report First Quarter 2023 Results and Provide Business Update

May 4, 2023

Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update

March 7, 2023

Evolus Initiates Nuceiva® Launch in Germany and Austria

February 26, 2023

Evolus to Report Fourth Quarter and Year End 2022 Results and Provide Business Update

February 21, 2023

Evolus Receives Regulatory Approval for Nuceiva® in Australia

January 22, 2023

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau®/Nuceiva® Revenue Aspiration

January 17, 2023

Calls in 2023

Decks in 2023